(LBRX) LB Pharmaceuticals Common - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US50180M1080
Stock: Neuropsychiatric Drugs, Schizophrenia Treatment, Bipolar Depression Therapy
Total Rating 43
Risk 74
Buy Signal 0.83
| Risk 5d forecast | |
|---|---|
| Volatility | 57.2% |
| Relative Tail Risk | -7.08% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.51 |
| Alpha | 35.89 |
| Character TTM | |
|---|---|
| Beta | 0.695 |
| Beta Downside | 3.076 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.57% |
| CAGR/Max DD | 8.50 |
Description: LBRX LB Pharmaceuticals Common March 04, 2026
LB Pharmaceuticals Inc. (LBRX) is a clinical-stage biopharmaceutical company focused on neuropsychiatric disease therapies.
The companys primary asset is LB-102, an oral small molecule. This drug is currently in Phase 3 clinical trials for acute schizophrenia. It has completed Phase 1 trials for bipolar I depression and is in preclinical development for a long-acting injectable (LAI) formulation. Developing LAI formulations is a common strategy in psychiatry to improve patient adherence.
Founded in 2015, LB Pharmaceuticals operates within the biotechnology sector, where drug development is a lengthy and capital-intensive process.
Further research on ValueRay can provide more in-depth analysis of LBRXs pipeline and market position.
Headlines to watch out for
- LB-102 Phase 3 trial results for schizophrenia impact stock
- Successful development of LAI formulation expands market
- Regulatory approval process for LB-102 drives valuation
- Competition in neuropsychiatric drug market affects revenue
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 19.37 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.07 > 3% & CFO -22.8m > Net Income -18.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 47.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.3m) vs 12m ago 12.73% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -3.04 > 6 (EBITDA TTM -13.9m / Interest Expense TTM 4.66m) |
Altman Z'' -7.17
| A: 0.97 (Total Current Assets 316.4m - Total Current Liabilities 6.65m) / Total Assets 320.7m |
| B: -0.37 (Retained Earnings -118.1m / Total Assets 320.7m) |
| C: -0.08 (EBIT TTM -14.1m / Avg Total Assets 183.2m) |
| D: -11.22 (Book Value of Equity -118.1m / Total Liabilities 10.5m) |
| Altman-Z'' Score: -7.17 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 0.0/0.0) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: none (AQ_t 0.00 / AQ_t-1 0.0) |
| SGI: none (Revenue 0.0 / 0.0) |
| TATA: 0.01 (NI -18.8m - CFO -22.8m) / TA 320.7m) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of LBRX shares?
As of March 17, 2026, the stock is trading at USD 26.46 with a total of 383,209 shares traded.
Over the past week, the price has changed by +8.71%, over one month by +9.70%, over three months by +33.50% and over the past year by +52.95%.
Over the past week, the price has changed by +8.71%, over one month by +9.70%, over three months by +33.50% and over the past year by +52.95%.
Is LBRX a buy, sell or hold?
LB Pharmaceuticals Common has no consensus analysts rating.
What are the forecasts/targets for the LBRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.5 | 68.2% |
| Analysts Target Price | - | - |
LBRX Fundamental Data Overview March 17, 2026
P/B = 2.1016
Revenue TTM = 0.0 USD
EBIT TTM = -14.1m USD
EBITDA TTM = -13.9m USD
Long Term Debt = 3.67m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 730k USD (from shortTermDebt, last quarter)
Debt = 3.67m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -266.1m USD (from netDebt column, last quarter)
Enterprise Value = 338.6m USD (649.4m + Debt 3.67m - CCE 314.5m)
Interest Coverage Ratio = -3.04 (Ebit TTM -14.1m / Interest Expense TTM 4.66m)
EV/FCF = -14.71x (Enterprise Value 338.6m / FCF TTM -23.0m)
FCF Yield = -6.80% (FCF TTM -23.0m / Enterprise Value 338.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 81.0k) / Revenue TTM)
Tobins Q-Ratio = 1.06 (Enterprise Value 338.6m / Total Assets 320.7m)
Interest Expense / Debt = 127.1% (Interest Expense 4.66m / Debt 3.67m)
Taxrate = 21.0% (US default 21%)
NOPAT = -11.2m (EBIT -14.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 47.60 (Total Current Assets 316.4m / Total Current Liabilities 6.65m)
Debt / Equity = 0.01 (Debt 3.67m / totalStockholderEquity, last quarter 310.2m)
Debt / EBITDA = 19.13 (negative EBITDA) (Net Debt -266.1m / EBITDA -13.9m)
Debt / FCF = 11.56 (negative FCF - burning cash) (Net Debt -266.1m / FCF TTM -23.0m)
Total Stockholder Equity = 30.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.26% (Net Income -18.8m / Total Assets 320.7m)
RoE = -61.56% (Net Income TTM -18.8m / Total Stockholder Equity 30.5m)
RoCE = -41.34% (EBIT -14.1m / Capital Employed (Equity 30.5m + L.T.Debt 3.67m))
RoIC = -29.98% (negative operating profit) (NOPAT -11.2m / Invested Capital 37.3m)
WACC = 8.42% (E(649.4m)/V(653.1m) * Re(8.47%) + (debt cost/tax rate unavailable))
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.73%
[DCF] Fair Price = unknown (Cash Flow -23.0m)
EPS Correlation: 100.00 | EPS CAGR: 60.4k% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-3.71 | Chg7d=+0.000 | Chg30d=+0.017 | Revisions Net=+0 | Growth EPS=+21.5% | Growth Revenue=+0.0%
Revenue TTM = 0.0 USD
EBIT TTM = -14.1m USD
EBITDA TTM = -13.9m USD
Long Term Debt = 3.67m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 730k USD (from shortTermDebt, last quarter)
Debt = 3.67m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -266.1m USD (from netDebt column, last quarter)
Enterprise Value = 338.6m USD (649.4m + Debt 3.67m - CCE 314.5m)
Interest Coverage Ratio = -3.04 (Ebit TTM -14.1m / Interest Expense TTM 4.66m)
EV/FCF = -14.71x (Enterprise Value 338.6m / FCF TTM -23.0m)
FCF Yield = -6.80% (FCF TTM -23.0m / Enterprise Value 338.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 81.0k) / Revenue TTM)
Tobins Q-Ratio = 1.06 (Enterprise Value 338.6m / Total Assets 320.7m)
Interest Expense / Debt = 127.1% (Interest Expense 4.66m / Debt 3.67m)
Taxrate = 21.0% (US default 21%)
NOPAT = -11.2m (EBIT -14.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 47.60 (Total Current Assets 316.4m / Total Current Liabilities 6.65m)
Debt / Equity = 0.01 (Debt 3.67m / totalStockholderEquity, last quarter 310.2m)
Debt / EBITDA = 19.13 (negative EBITDA) (Net Debt -266.1m / EBITDA -13.9m)
Debt / FCF = 11.56 (negative FCF - burning cash) (Net Debt -266.1m / FCF TTM -23.0m)
Total Stockholder Equity = 30.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.26% (Net Income -18.8m / Total Assets 320.7m)
RoE = -61.56% (Net Income TTM -18.8m / Total Stockholder Equity 30.5m)
RoCE = -41.34% (EBIT -14.1m / Capital Employed (Equity 30.5m + L.T.Debt 3.67m))
RoIC = -29.98% (negative operating profit) (NOPAT -11.2m / Invested Capital 37.3m)
WACC = 8.42% (E(649.4m)/V(653.1m) * Re(8.47%) + (debt cost/tax rate unavailable))
Discount Rate = 8.47% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.73%
[DCF] Fair Price = unknown (Cash Flow -23.0m)
EPS Correlation: 100.00 | EPS CAGR: 60.4k% | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=-3.71 | Chg7d=+0.000 | Chg30d=+0.017 | Revisions Net=+0 | Growth EPS=+21.5% | Growth Revenue=+0.0%